Search clinical trials for: BI 1744

Total 1322 results

Boehringer Ingelheim

Withdrawn

BI 705564 in Patients With Systemic Lupus Erythematosus (SLE)

Lupus Erythematosus, Systemic
Boehringer Ingelheim

Withdrawn

This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 705564 Are Taken up in the Body and How Well They Are Tolerated

Healthy
Boehringer Ingelheim

Withdrawn

A Study to Test Different Doses of BI 730357 and Find Out Whether They Reduce Symptoms in People With Active Psoriatic Arthritis

Arthritis, Psoriatic
Boehringer Ingelheim

Completed

A Study About How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated in Healthy Japanese Men

Healthy

Japan
Boehringer Ingelheim

Completed

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 764198 Are Tolerated

Healthy

Japan
Boehringer Ingelheim

Completed

To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1467335 Following Multiple Dose Administration Over 28 Days

Healthy

Germany
Boehringer Ingelheim

Completed

This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)

Diabetic Nephropathies

United States, Canada, Belgium, Czechia, Germany
Boehringer Ingelheim

Completed

BI 443651 Multiple Rising Dose in Healthy Volunteers Followed by a Cross-over in CF Subjects

Cystic Fibrosis

Germany, United Kingdom
Boehringer Ingelheim

Completed

Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906 in Healthy Male Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

Safety and Tolerability of BI 685509 in Healthy Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

This Study Tests How Healthy Men Tolerate Different Doses of BI1015550. The Study Also Tests How BI 1015550 is Taken up by the Body

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID and Multiple Doses of BI 207127 Combined With Faldaprevir in Healthy Male and Female Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

Study to Explore Pharmacokinetics and Pharmacodynamics of a Single Rising Dose of BI 135585 XX

Healthy

Germany
Far Eastern Memorial Hospital

Unknown

Effect of Bi-ventricular Pacing on Autonomous Nervous System

Congestive Heart Failure
Lipocine Inc.

Active, not recruiting

A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial

NASH - Nonalcoholic Steatohepatitis

United States
Boehringer Ingelheim

Completed

Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)

Pulmonary Disease, Chronic Obstructive

United States, Canada, Germany
Reata, a wholly owned subsidiary of Biogen

Terminated

RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases

Brain Metastases

United States
Centre Hospitalier Universitaire Dijon

Completed

Effects of OM-174 in Adult Patients With Solid Tumors (OM-174)

Solid Tumors
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 671800 HEA in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Not yet recruiting

A Study in Healthy People to Test How BI 1015550 is Taken up in the Body When Given With or Without Food

Healthy
Boehringer Ingelheim

Recruiting

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 3006337 Are Tolerated

Healthy

Japan
University Hospital, Akershus
University of Oslo

Recruiting

Brief Intervention for Sleep Medication Misuse Among Elderly (BI-sleep)

Harmful Use of Hypnotic

Norway
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 764532 in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Neuroendocrine Neoplasms | Small Cell Lung Carcinoma (SCLC)

Germany, Belgium, Japan, France
Boehringer Ingelheim

Recruiting

A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)

Bronchiectasis | Cystic Fibrosis

United States, Germany, Spain, Belgium, Netherlands, France, Italy
Boehringer Ingelheim

Recruiting

A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated

Healthy

Japan
Boehringer Ingelheim

Recruiting

A Study to Test Different Doses of BI 1831169 Alone and in Combination With Ezabenlimab in People With Different Types of Advanced Cancer (Solid Tumors)

Solid Tumors

United States, Spain, Germany, Austria, France, Belgium
Boehringer Ingelheim

Recruiting

A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)

Neoplasms

Spain, United States, Belgium, Japan, Netherlands, Italy
Boehringer Ingelheim

Recruiting

A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface

Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms

United States, Canada
Boehringer Ingelheim

Recruiting

This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)

Neoplasms

Belgium, Korea, Republic of, United States, Spain, Germany, Japan, Poland, Israel, Sweden, Denmark, Canada
Boehringer Ingelheim

Completed

A Study to Test How Different Doses of BI 765423 Are Taken up in the Body of Healthy Men

Healthy

Belgium
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 474121 is Tolerated

Healthy

Japan
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How the Body Takes up and Tolerates Different Doses of BI 765080

Healthy

Belgium
Boehringer Ingelheim

Active, not recruiting

A Study in Healthy Japanese Men to Test How Different Doses of BI 1569912 Are Taken up by the Body and How Well They Are Tolerated

Healthy

Japan
Boehringer Ingelheim

Completed

BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours

Neoplasms

Belgium
Boehringer Ingelheim

Completed

This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 730357 Are Taken up in the Body and How Well They Are Tolerated

Healthy

Japan
Boehringer Ingelheim

Completed

A Study in Healthy Men to Find Out How Well Different Doses of BI 764122 Are Tolerated and Whether Food Affects the Amount of BI 764122 in the Blood

Healthy

Belgium
Boehringer Ingelheim

Completed

A Study to Test How Well Men Tolerate Different Doses of BI 3006337

Healthy

Belgium, Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Different Doses of BI 1584862 Are Tolerated and How BI 1584862 is Taken up in the Body With or Without Food

Healthy

Germany
Boehringer Ingelheim

Terminated

A Study to Test Long-term Treatment With Spesolimab in Patients With Fistulising Crohn's Disease Who Took Part in Previous Trials

Crohn Disease

Belgium, Germany, Austria, Netherlands, Korea, Republic of
Boehringer Ingelheim

Completed

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 1291583 Are Tolerated

Healthy

Japan
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated and Taken up by the Body With or Without Food

Healthy

Germany
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How Different Doses of BI 1265162 Are Taken up in the Body and How Well They Are Tolerated.

Healthy

Germany
Boehringer Ingelheim

Completed

A Trial in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are Tolerated

Healthy

Germany
Boehringer Ingelheim

Terminated

A Study in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are Tolerated

Healthy

Germany
Boehringer Ingelheim

Terminated

A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated and How Food Influences the Amount of BI 1569912 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men Tests How Different Doses of BI 764198 Are Taken up in the Body and How Well They Are Tolerated.

Healthy

Germany
Boehringer Ingelheim

Completed

This Study Tests BI 1467335 in Healthy Japanese and Caucasian Men. The Study Tests How Different Doses of BI 1467335 Are Taken up in the Body and How Well They Are Tolerated

Healthy

Japan
Boehringer Ingelheim

Completed

A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated. (ROBIN)

Diabetic Retinopathy

United States, Spain, Italy, United Kingdom, Austria, Greece, Norway, Portugal
Boehringer Ingelheim

Completed

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

Non-alcoholic Fatty Liver Disease

United States, Spain, United Kingdom, Belgium, Canada, Germany, Netherlands, France, Ireland
Bezmialem Vakif University

Unknown

Comparison of Follow-up Protocols in Terms of Fetal, Neonatal and Maternal Results in Intrauterine Growth Retardation

Intrauterine Growth Restriction | Fetal Surveillance

Turkey

3

Subscribe